Tag Archives: macular degeneration

Methods The leading journals that publish basic science and clinical research in the area of cardiovascular and ophthalmological diseases, and MEDLINE using PubMed, were scanned. The main terms used were “age-related macular degeneration”, “cardiovascular disease”, “ranibizumab”, “bevacizumab”, “pegaptanib” and “VEGF”. The publications were largely selected from the past five years, but older publications which are commonly referenced or highly regarded were not excluded. The reference lists of articles identified by this search strategy were screened and relevant articles were selected. Review articles are cited to pr

Efficacy The Vascular Endothelial Growth Factor Inhibition Study in Ocular Neovascularization (VISION) trial showed that 70% of patients with wet AMD treated for 12 months with six-weekly pegaptanib sodium responded to treatment (lost <15 letters). This compared with only 55% of control (sham) subjects. Furthermore, 6% of patients receiving pegaptanib experienced an improvement in their vision (gained ≥15 letters).2 In a retrospective analysis performed to acquire data on ‘real-life’ experience with pegaptanib, data were collected from 164 patients with any angiographic subtype of sub-foveal choroidal neovascularisation secondary to